Phase 3Recruiting
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
- Sponsor
- CMG Pharmaceutical Co. Ltd (Industry)
- Enrolment
- 240 planned
- Conditions
- Dyslipidemia; Type 2 Diabetes
- Interventions
- CMG190303(Dapagliflozin/Rosuvastatin); Comparator 1: Dapagliflozin/Rosuvastatin placebo; Rosuvastatin/Dapagliflozin placebo
- Ages
- adults, older adults
- Registry
- NCT06772168
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303. The main questions it aims to answer are: -Primary Objectives: 1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin 2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin
Primary outcomes
- To compare the change in HbA1c (%)
- To compare the percentage change in LDL-C
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started